MLYS — Mineralys Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1933414 ·
Last close
$14.48
Market Cap
$1.28B
52W High
$44.99
52W Low
$14.30
ADV30
1,808,812
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -60,087,000 -57,328,000 630,123,000 101,273,000 126,348,000
Jun 2026 0 — -246,040,000 -241,071,000 667,853,000 138,268,000 116,936,000
Mar 2026 0 — -45,340,000 -39,339,000 652,862,000 112,779,000 14,718,000
Dec 2025 0 — -38,280,000 -32,234,000 661,806,000 172,921,000 15,113,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-153,011,000
Investing CF
$-328,951,000
Financing CF
$365,638,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.36
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-794,907,000
Inventory
—
Receivables
—
ST Investments
$523,399,000
EBIT TTM
$-383,800,000
Pretax Income TTM
$-369,972,000
Interest Exp TTM
$3,188,000
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -170,604,000 -154,651,000 661,806,000 15,113,000 646,693,000 -142,416,000
Dec 2024 0 -192,403,000 -177,810,000 205,903,000 14,646,000 191,257,000 -166,314,000
Dec 2023 0 -84,657,000 -71,898,000 251,636,000 10,482,000 241,154,000 -81,173,000
Dec 2022 0 -31,479,000 -29,799,000 114,442,000 166,711,000 -52,269,000 -29,221,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-349,576,000
OpCashFlow TTM
—
Assets (Latest)
$667,853,000
Forward EPS
$-2.66

Max Pain — expiry 2027-01-15

max pain strike: $20.00 · spot: $13.78 · call oi: 30,971 · put oi: 1,687
Expected Move to 2027-01-15: ±$6.20 (44.99%) — implied range $7.58 – $19.98 · ATM straddle on $15.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GENB Generate Biomedicines, Inc. $1.27B $9.84 —
INVA Innoviva, Inc. $1.30B $18.30 —
GPCR Structure Therapeutics Inc. $1.30B $18.17 —
LBRX LB PHARMACEUTICALS INC $1.30B $40.30 —
MNKD MANNKIND CORP $1.31B $4.07 —

News headlines (Yahoo Finance, 1h cache)

Mineralys stock gains after drug shows sustained blood pressure cuts
2026-11-09 17:59 · Yahoo
Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
2026-11-08 21:35 · Yahoo
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 13:00 · Yahoo
Mineralys Therapeutics Inc (MLYS) Q3 2026 Earnings Call Highlights: Strong Phase 3 Data and ...
2026-11-05 07:13 · Yahoo
Mineralys Therapeutics (MLYS) Publishes Lorundrostat CKD Data, Is The Stock Still A Bargain?
2026-11-05 05:18 · Yahoo
What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call
2026-11-05 03:14 · Yahoo
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-04 21:05 · Yahoo
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
2026-11-03 21:05 · Yahoo
Kidney Trial Results Could Change The Case For Mineralys Therapeutics Stock
2026-11-01 10:12 · Yahoo
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
2026-10-28 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.